PUBLISHED EVIDENCE

What has actually been studied

Twelve verified publications, rendered from this site’s research database with design, participants, intervention, comparator, endpoint, result, limitations, conflicts, evidence category and Panacea’s interpretation. Positive and negative evidence appear at equal dignity — nothing is hidden.

What has been demonstrated

measurable anticoagulant and antithrombotic pharmacology
fractions interact with antithrombin III and heparin cofactor II
investigated in chronic venous disease
investigated in recurrent venous thromboembolism
human mechanistic glycocalyx research
experimental nitric-oxide-pathway research
human endothelial-biomarker research after COVID-19
animal and cellular permeability and inflammatory research

What has not been demonstrated

universal glycocalyx regeneration
elimination of all plaques
destruction of SARS-CoV-2 spike protein
removal of vaccine-derived material
guaranteed microclot clearance
reversal of every long-COVID case
reversal of all endothelial disease
replacement for standard anticoagulation
established benefit in every diabetic nephropathy
freedom from bleeding or interaction risk
acceptable risk profile of unregulated injectables
superiority over all established vascular medicines

Chronic venous disease

The positive multicentre ulcer trial and the Cochrane limitation, displayed together.

The trial signal

Published human trialModerate

Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers

Coccheri S, et al. · Thrombosis and Haemostasis, 87(6):947–952 · 2002

doi:10.1055/s-0037-1613116 ↗ · PMID 12083500

Design: Randomized, double-blind, multicentre, placebo-controlled
Participants / model: 235
Intervention: Sulodexide plus standard local care/compression for 3 months
Comparator: Placebo plus standard local care/compression
Endpoint: Complete ulcer healing
Result: Higher complete healing at 2 months (p=0.018) and 3 months; NNT 7 (2 months) and 5 (3 months); ulcer-area reduction and fibrinogen decrease in the sulodexide arm only.
Limitations: 3-month horizon; no long-term recurrence data in the abstract. Bibliographic note: the DOI was assigned retrospectively by Crossref; the PubMed record carries no DOI.
Conflicts: None declared in the verified record.

Panacea interpretation · A real signal, displayed together with the Cochrane limitation (S12) — one does not exist on this page without the other.

The evidence limitation

Systematic reviewLow-quality evidence base (Cochrane)

Sulodexide for treating venous leg ulcers

Wu B, Lu J, Yang M, Xu T · Cochrane Database of Systematic Reviews, (6):CD010694 (update of 2014 original) · 2016

doi:10.1002/14651858.CD010694.pub2 ↗ · PMID 27251175

Design: Cochrane systematic review and meta-analysis (4 RCTs)
Participants / model: 4 RCTs, 463 participants (3 RCTs in the meta-analysis)
Intervention: Sulodexide as adjuvant to local care
Comparator: Local care alone
Endpoint: Complete ulcer healing; adverse events
Result: Complete healing 49.4% (sulodexide adjuvant) vs 29.8% (local care alone), RR 1.66 (95% CI 1.30–2.12) — rated LOW quality (risk of bias). Adverse events 4.4% vs 3.1%, RR 1.44 (95% CI 0.48–4.34) — VERY LOW quality; unclear whether sulodexide is associated with any increase in adverse events.
Limitations: Few small trials, high risk of bias (one abstract-only); dosing/route unclear; conclusions likely to change with new research.
Conflicts: None declared in the verified record.

Panacea interpretation · The evidence limitation: sulodexide might improve ulcer healing, on low-quality evidence, with adverse effects uncertain. This page does not hide it.

Systematic reviewModerate

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Bignamini AA, Matuška J · Advances in Therapy, 37(3):1013–1033 · 2020

doi:10.1007/s12325-020-01232-1 ↗ · PMID 31989486

Design: Systematic review and meta-analysis
Participants / model: 23 studies / 7,153 participants; 13 studies (1,901 participants) with extractable quantitative data
Intervention: Sulodexide, various regimens
Comparator: Various comparators
Endpoint: Symptoms and signs of chronic venous disease; adverse events
Result: Reduced pain, cramps, heaviness, oedema, total symptom score and inflammatory mediators; adverse-event risk not different vs comparator (RR 1.31, 95% CI 0.74–2.32); overall adverse-event rate ~3%.
Limitations: Of 64 identified studies only 13 had extractable quantitative data — a thin, heterogeneous evidence base.
Conflicts: None declared in the verified record.

Panacea interpretation · Supports chronic venous disease as the most clinically studied area — with a visibly thin quantitative base.

Recurrent venous thromboembolism

SURVET applies after completed conventional anticoagulation in first unprovoked VTE — it is not permission to substitute prescribed anticoagulation.

Published human trialModerate (single large RCT)

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Andreozzi GM, Bignamini AA, et al. · Circulation, 132(20):1891–1897 · 2015

doi:10.1161/CIRCULATIONAHA.115.016930 ↗ · PMID 26408273

Design: Multicentre, randomized, double-blind, placebo-controlled (EudraCT 2009-016923-77)
Participants / model: 615 (307 sulodexide / 308 placebo)
Intervention: Sulodexide 500 LRU twice daily for 2 years, after 3–12 months of conventional anticoagulation for a first unprovoked VTE
Comparator: Placebo
Endpoint: Recurrent venous thromboembolism
Result: Recurrence 15/307 vs 30/308 (HR 0.49; 95% CI 0.27–0.92; p=0.02). No major bleeding; 2 clinically relevant bleeds per arm.
Limitations: Applies only to extended secondary prevention after completed conventional anticoagulation for a first unprovoked VTE — not treatment of active VTE, and not permission to substitute prescribed anticoagulation.
Conflicts: None declared in the verified record.

Panacea interpretation · A well-defined clinical context: secondary prevention after completed anticoagulation, nothing broader.

Why promising mechanisms do not guarantee successful clinical outcomes

Earlier reports had suggested effects on albuminuria in diabetic kidney disease. The large, well-designed Sun-MACRO trial then tested renoprotection directly — and returned a null result, terminated early and underpowered relative to design. It is displayed here at full dignity: sulodexide has not been conclusively shown to reverse diabetic nephropathy.

Published human trialMixed/Negative (high-quality RCT, null result)

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

Packham DK, et al. · Journal of the American Society of Nephrology, 23(1):123–130 · 2012

doi:10.1681/ASN.2011040378 ↗ · PMID 22034636

Design: Randomized, double-blind, placebo-controlled (Sun-MACRO); terminated early
Participants / model: 1,248 enrolled (2,240 planned)
Intervention: Sulodexide in type 2 diabetes with renal impairment and proteinuria >900 mg/day on maximal ARB therapy
Comparator: Placebo
Endpoint: Composite: doubling of serum creatinine, ESRD, or creatinine ≥6.0 mg/dL
Result: No significant difference in the composite endpoint: 26 events on sulodexide vs 30 on placebo. Side effects similar.
Limitations: Terminated before planned enrolment — underpowered relative to design.
Conflicts: None declared in the verified record.

Panacea interpretation · Why promising mechanisms do not guarantee successful clinical outcomes. This trial is why Panacea’s programme insists on measurement before interpretation.

Endothelial glycocalyx

The key human mechanistic study — glycocalyx measurements in type 2 diabetes. Mechanistic and limited; not evidence of universal regeneration.

Human mechanistic studyPreliminary (non-randomized pilot)

Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H · Diabetologia, 53(12):2646–2655 · 2010

doi:10.1007/s00125-010-1910-x ↗ · PMID 20865240

Design: Prospective, non-randomized, unblinded pilot intervention (NTR780 / ISRCTN82695186)
Participants / model: 10 male participants with type 2 diabetes + 10 matched controls
Intervention: Sulodexide 200 mg/day orally for 2 months
Comparator: Matched untreated controls; within-participant pre/post
Endpoint: Sublingual glycocalyx (sidestream dark-field imaging), retinal glycocalyx (angiography), transcapillary escape rate of albumin (TERalb)
Result: Baseline sublingual glycocalyx 0.64 vs 0.78 µm (T2DM vs control); retinal 5.38 vs 8.89 µm; TERalb 5.6±2.3% vs 3.7±1.7%. On sulodexide: sublingual → 0.93 µm, retinal → 5.88 µm; TERalb trend → 4.0±2.3%; hyaluronidase decreased.
Limitations: Tiny sample, no placebo or randomization, 2-month follow-up; the authors call for long-term outcome studies. A limited mechanistic study — not evidence that sulodexide universally regenerates the human vascular system.
Conflicts: None declared in the verified record.

Panacea interpretation · The study that makes glycocalyx interaction a serious research question — and its design limits are why Panacea treats mechanism, measurement and scale as separate problems.

Vascular relaxation

Isolated vascular segments, ex vivo — not clinical proof in humans.

Ex-vivo studyPreclinical

Sulodexide Promotes Arterial Relaxation via Endothelium-Dependent Nitric Oxide-Mediated Pathway

Raffetto JD, Calanni F, Mattana P, Khalil RA · Biochemical Pharmacology, 166:347–356 · 2019

doi:10.1016/j.bcp.2019.04.021 ↗ · PMID 31014752

Design: Ex vivo tissue-bath myography on isolated rat vessels
Participants / model: Isolated male rat abdominal aorta and mesenteric artery rings
Intervention: Acute sulodexide exposure on phenylephrine-precontracted vessels
Comparator: Endothelium-denuded rings; L-NAME inhibition; SNP (endothelium-independent) control
Endpoint: Vasorelaxation; nitrate/nitrite production
Result: Concentration-dependent, endothelium-dependent relaxation; abolished by endothelium removal and L-NAME; increased nitrate/nitrite; no effect on SNP-induced (endothelium-independent) relaxation.
Limitations: Ex vivo rodent vessels with supraphysiologic acute exposure; chronic in vivo human translation untested. Not clinical proof in humans.
Conflicts: Calanni and Mattana are Alfasigma employees.

Panacea interpretation · A clean mechanistic read-out on the NO pathway — ex vivo evidence, and presented as exactly that.

COVID-19 convalescent endothelium

Biomarker research. It does not demonstrate spike-protein destruction, microclot removal or a universal long-COVID treatment — it is a legitimate basis for further research.

Published human trialPreliminary (single RCT, surrogate endpoints)

Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients

Gonzalez-Ochoa AJ, et al. · Clinical and Applied Thrombosis/Hemostasis, vol 31 · 2025

doi:10.1177/10760296241297647 ↗ · PMID 39763448

Design: Double-blind, single-center, randomized, placebo-controlled trial (Mexico)
Participants / model: 206 analysed (103 sulodexide / 103 placebo)
Intervention: Sulodexide 250 LRU orally twice daily for 8 weeks, in early convalescence
Comparator: Placebo
Endpoint: Endothelial-dysfunction biomarkers (thrombomodulin primary)
Result: Significantly lower thrombomodulin, von Willebrand factor and IL-6 vs placebo at week 8; D-dimer and CRP also lower; no difference in P-selectin, fibrinogen, VCAM-1 or ICAM-1.
Limitations: Single-center; surrogate biomarker endpoints, not clinical outcomes. Biomarker changes do not demonstrate spike-protein destruction, microclot removal, or a universal long-COVID treatment.
Conflicts: First author disclosed consulting for Alfasigma Mexico.

Panacea interpretation · A legitimate vascular research question — not a completed clinical answer. Supports Panacea’s dedicated post-viral endothelial-dysfunction track (pillar 5).

Published human trialPreliminary

Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial

Gonzalez-Ochoa AJ, et al. · Thrombosis and Haemostasis, 121(7):944–954 · 2021

doi:10.1055/a-1414-5216 ↗ · PMID 33677827

Design: Randomized, placebo-controlled outpatient trial
Participants / model: 243 per-protocol (124 sulodexide / 119 placebo); intention-to-treat also reported
Intervention: Sulodexide 1000 LRU/day for 21 days, in high-risk outpatients within 3 days of symptom onset
Comparator: Placebo
Endpoint: Hospitalisation, supplemental oxygen, inflammatory and coagulation markers
Result: Hospitalisation 17.7% vs 29.4% (p=0.03); less supplemental oxygen (30% vs 42%, p=0.05); lower D-dimer >500 ng/dL rates and CRP; no differences in thromboembolic events, major bleeding or mortality.
Limitations: The authors state the results should be confirmed; no mortality or thrombosis benefit was shown.
Conflicts: First author disclosed unrelated Alfasigma Mexico research ties.

Panacea interpretation · Supports the post-viral research question; does not establish any treatment protocol.

Published human trialPreliminary

Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study

Charfeddine S, et al. · Frontiers in Cardiovascular Medicine, 9:866113 · 2022

doi:10.3389/fcvm.2022.866113 ↗ · PMID 35647070

Design: Multicenter prospective QUASI-EXPERIMENTAL study — not randomized, no placebo
Participants / model: 290 (144 sulodexide / 146 no-treatment control)
Intervention: Sulodexide, 21 days
Comparator: No-treatment control group
Endpoint: Endothelial quality index (EQI), chest pain, palpitations
Result: At 21 days, greater improvement in chest pain (83.7% vs 43.6%), palpitations (85.2% vs 52.9%) and endothelial quality index (median ΔEQI 0.66 vs 0.18); endothelial improvement correlated with symptom recovery.
Limitations: Quasi-experimental, non-randomized, no placebo control; 21-day follow-up. This study must never be described as an RCT.
Conflicts: None declared in the verified record.

Panacea interpretation · Interesting and hypothesis-generating; its non-randomized design is exactly why Panacea treats post-viral endothelium as an open research question.

Sepsis — preclinical

Endothelial-cell and animal sepsis research with a small paediatric biomarker cohort. Preclinical — not evidence of human sepsis efficacy.

Animal studyPreclinical

Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis

Ying J, Zhang C, Wang Y, Liu T, Yu Z, Wang K, Chen W, Zhou Y, Lu G · Frontiers in Immunology, 14:1172892 · 2023

doi:10.3389/fimmu.2023.1172892 ↗ · PMID 37614234

Design: Three arms: (1) clinical cohort of 28 children with septic shock (PICU, Fudan) with plasma heparan sulfate/syndecan-1 on days 1 and 3; (2) heparinase-III-induced glycocalyx shedding in endothelial cells; (3) mouse sepsis models (LPS and CLP) treated with sulodexide
Participants / model: 28-child PICU cohort; endothelial-cell experiments; mouse models
Intervention: Sulodexide in cell and mouse sepsis models
Comparator: Model controls
Endpoint: Permeability assays, lung histopathology, wet/dry ratio, survival
Result: Sulodexide improved vascular permeability measures in the sepsis models, consistent with glycocalyx remodelling; the paediatric cohort provided biomarker context (heparan sulfate, syndecan-1).
Limitations: Small single-center pediatric cohort; animal dosing not translated to humans. Preclinical sepsis research — not evidence of human sepsis efficacy.
Conflicts: None declared in the verified record.

Panacea interpretation · Connects glycocalyx state to permeability in sepsis models; Panacea presents it strictly as preclinical work.

Peripheral arterial disease

Systematic reviewModerate

Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis

Gaddi AV, et al. · JRSM Cardiovascular Disease, 9:2048004020907002 · 2020

doi:10.1177/2048004020907002 ↗ · PMID 32110390

Design: Systematic review and meta-analysis (PRISMA) of 11 double-blind trials
Participants / model: 11 double-blind trials
Intervention: Sulodexide, 90 days
Comparator: Various
Endpoint: Initial Claudication Distance / pain-free walking distance
Result: Initial Claudication Distance difference +68.9 m (95% CI ±11.9 m; p<0.001) after 90 days of sulodexide; improved pain-free walking distance and quality of life.
Limitations: Possible publication bias (funnel-plot deviation); the headline effect is a within-sulodexide pre-post change, not a sulodexide-vs-placebo contrast; the authors call for further progression studies.
Conflicts: None declared in the verified record.

Panacea interpretation · A functional endpoint signal whose design caveat (pre-post, not vs placebo) must travel with the number.